-

Dr Ryan Cross – Immunology division

14/02/2024 1:00 pm - 14/02/2024 2:00 pm
Location
Davis Auditorium

WEHI Wednesday Seminar hosted by Professor Misty Jenkins
 

Dr Ryan Cross
Senior Research Officer – Jenkins Laboratory; Immunotherapy Program – The Brain Cancer Centre; Immunology division – Infection, Inflammation & Immune Theme, WEHI 

 

Developing Novel Synthetic Immunotherapies for Glioblastoma

 

Davis Auditorium

Join via SLIDO enter code #WEHIWednesday

Including Q&A session
 

  

Glioblastoma multiforme is a highly malignant type of brain tumour that is known for its rapid growth and invasive characteristics, which poses a formidable challenge in the field of neuro oncology due to its aggressive nature and limited treatment options. Traditional treatments, such as surgery, radiation, and chemotherapy, have shown limited success in extending survival of people with glioblastoma, highlighting the urgent need for innovative therapeutic approaches.

 

Immunotherapy, specifically Chimeric Antigen Receptor (CAR) T cell adoptive cell therapy, has emerged as a promising avenue in the treatment of brain cancer. CARs are a synthetic receptor that we can design to modify the body’s immune cells to specifically target and destroy glioblastoma cancer cells, leaving healthy brain cells untouched. To develop novel CAR T cell therapies for glioblastoma we have employed cell surface proteomics of primary tumours to identify novel targets. In parallel we have developed a pipeline for the creation and preclinical validation of novel CARs from antibody screening through to orthotopic tumour implantation models. 

 

In addition to the development of novel targeting CAR pipeline we are also exploring the integration of synthetic biology logic circuits to enhance the efficacy and safety of our CAR T cells therapies. Using cutting-edge technologies, such as SNIPRs and synTF, we hope to gain precise control and customisation of the immune cells. We believe that through the integration of logic gated systems in CAR T cell therapy we can develop effective and safe immunotherapies for glioblastoma patients and their families. 

 

All welcome!

Support us

Together we can create a brighter future

Your support will help WEHI’s researchers make discoveries and find treatments to ensure healthier, longer lives for you and your loved ones.

Sign up to our quarterly newsletter Illuminate

Find out about recent discoveries, community supporters and more.

Illuminate Summer 2023
View the current issue